# Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma

> **NCT06737146** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Suzhou Maximum Bio-tech Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- High-grade Glioma

## Interventions

- **DRUG:** MT027 cells suspension

## Key facts

- **NCT ID:** NCT06737146
- **Lead sponsor:** Suzhou Maximum Bio-tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06737146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06737146, "Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06737146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*